[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. Nishimura N, Urade M, Hashitani S, Noguchi K, Manno Y, Takaoka K, Sakurai K: Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib. J Oral Pathol Med; 2004 Nov;33(10):614-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib.
  • Basal diet or diets containing 150, 500 and 1500 ppm of celecoxib, a selective COX-2 inhibitor, were given ad libitum to hamsters, and tumor development was observed.
  • Although all hamsters developed squamous cell carcinoma, the onset of tumor formation was delayed in a dose-dependent manner.
  • Also, tumor growth was retarded and survived animals were increased in the group of celecoxib treatment.
  • CONCLUSIONS: The COX-2 expression was increased during hamster cheek pouch chemical carcinogenesis.
  • [MeSH-major] Carcinoma, Squamous Cell / enzymology. Cyclooxygenase Inhibitors / administration & dosage. Isoenzymes / biosynthesis. Mouth Neoplasms / enzymology. Prostaglandin-Endoperoxide Synthases / biosynthesis. Sulfonamides / administration & dosage
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene. Animals. Apoptosis / drug effects. Blotting, Western. Celecoxib. Cheek. Cricetinae. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Dose-Response Relationship, Drug. Immunoenzyme Techniques. In Situ Nick-End Labeling. Male. Mesocricetus. Neovascularization, Pathologic / prevention & control. Pyrazoles

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15482328.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 0 / Pyrazoles; 0 / Sulfonamides; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


2. Jellinek N, Maloney ME: Escharotic and other botanical agents for the treatment of skin cancer: a review. J Am Acad Dermatol; 2005 Sep;53(3):487-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Escharotic and other botanical agents for the treatment of skin cancer: a review.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Nose Neoplasms / drug therapy. Phytotherapy. Plants, Medicinal. Skin Neoplasms / drug therapy
  • [MeSH-minor] Cheek / pathology. Complementary Therapies. Humans. Male. Middle Aged. Mohs Surgery. Ointments. Rumex. Sanguinaria. Scalp. Treatment Failure. Trifolium

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2005 Sep;53(3):523-5 [16112367.001]
  • (PMID = 16112359.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ointments
  • [Number-of-references] 64
  •  go-up   go-down


3. Segawa E, Hashitani S, Toyohara Y, Kishimoto H, Noguchi K, Takaoka K, Urade M: Inhibitory effect of sulindac on DMBA-induced hamster cheek pouch carcinogenesis and its derived cell line. Oncol Rep; 2009 Apr;21(4):869-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of sulindac on DMBA-induced hamster cheek pouch carcinogenesis and its derived cell line.
  • In order to investigate the involvement of cyclooxygenase (COX)-2 in oral carcinogenesis and chemoprevention for it, we examined the COX-2 expression during dimethylbenzanthracene (DMBA)-induced hamster cheek pouch carcinogenesis and the inhibitory effect of sulindac, a non-steroidal anti-inflammatory drug (NSAID), on the carcinogenesis and its derived squamous carcinoma cell line HCPC-1.
  • From the beginning of DMBA application, basal diet or diets containing sulindac 200 or 400 ppm were given to hamsters, and observation of tumor development and measurement of body weight were performed.
  • Immunohistochemical analysis revealed that COX-2 expression was increased toward carcinogenesis from epithelial dysplasia to squamous cell carcinoma (SCC).
  • All hamsters developed SCC, but the onset of carcinoma formation was significantly delayed up to 14.8 and 11.8 weeks in the 200 ppm, and 400 ppm sulindac group, respectively, as compared to 8.7 weeks in the control group.
  • Treatment with sulindac sulfide, an active metabolite of sulindac, caused inhibition of cell growth, PGE2 production and VEGF production in HCPC-1 cells in vitro.
  • These findings suggested the involvement of COX-2 in DMBA-induced hamster cheek pouch carcinogenesis and the chemopreventive potential of sulindac.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Mouth Neoplasms / prevention & control. Sulindac / therapeutic use
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene. Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Cheek. Cricetinae. Cyclooxygenase 2 / analysis. Dinoprostone / biosynthesis. Male. Mesocricetus. Mouth Mucosa. Neovascularization, Pathologic / prevention & control. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287981.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Vascular Endothelial Growth Factor A; 184SNS8VUH / Sulindac; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; EC 1.14.99.1 / Cyclooxygenase 2; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


Advertisement
4. Sawant SS, Kandarkar SV: Role of vitamins C and E as chemopreventive agents in the hamster cheek pouch treated with the oral carcinogen-DMBA. Oral Dis; 2000 Jul;6(4):241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of vitamins C and E as chemopreventive agents in the hamster cheek pouch treated with the oral carcinogen-DMBA.
  • OBJECTIVE: To evaluate the role of vitamins C and E as chemopreventive agents in oral carcinogenesis by optical and ultrastructural studies.
  • MATERIALS AND METHODS: The cheek pouch of male hamsters was treated with the oral carcinogen, dimethylbenz(a)anthracene (DMBA), to induce multiple tumour formation.
  • Vitamins C and E were applied either singly or in combination as a chemopreventive agent.
  • Paraffin and resin-embedded sections of the hamster cheek pouch were studied optically and ultrastructurally.
  • RESULTS: The epithelium of control hamsters showed hyperorthokeratosis and parakeratosis, but did not develop well differentiated squamous cell carcinoma (WDSCC).
  • Ninety percent of the animals treated with DMBA alone showed WDSCC while 10% of the animals developed papillomas.
  • A reduction in the yield (1.1 tumour/animal) and rate 60-80% of squamous cell carcinomas but not of papillomas (2.0 papillomas/animal) was observed in groups VI-VIII treated with DMBA and vitamins C and E singly or in combination as compared to those of DMBA only.
  • In animals treated with DMBA plus vitamins C and E, statistical significant decrease in the number of animals with tumours and mitotic basal cells was observed when compared with the DMBA treated group.
  • Control animals showed normal ultrastructural morphology while tumour-bearing animals showed basal lamina in a discontinuous, fragmented, broken and diffused basement membrane, with diminished lamina densa, fewer hemidesmosomes and invagination of the basal cell cytoplasmic processes in the subepithelium.
  • CONCLUSION: These results indicate that vitamin E singly or in combination with vitamin C plays a role in the inhibition of tumour cell growth.
  • [MeSH-major] 9,10-Dimethyl-1,2-benzanthracene / adverse effects. Anticarcinogenic Agents / therapeutic use. Antioxidants / therapeutic use. Ascorbic Acid / therapeutic use. Carcinogens / adverse effects. Mouth Mucosa / drug effects. Mouth Neoplasms / chemically induced. Vitamin E / therapeutic use
  • [MeSH-minor] Animals. Basement Membrane / drug effects. Basement Membrane / pathology. Carcinoma, Squamous Cell / chemically induced. Carcinoma, Squamous Cell / pathology. Cheek. Chemoprevention. Chi-Square Distribution. Cricetinae. Cytoplasm / drug effects. Cytoplasm / ultrastructure. Drug Combinations. Epithelium / drug effects. Epithelium / pathology. Hemidesmosomes / drug effects. Hemidesmosomes / ultrastructure. Leukoplakia, Oral / chemically induced. Leukoplakia, Oral / pathology. Male. Mesocricetus. Mitosis / drug effects. Papilloma / chemically induced. Papilloma / pathology. Parakeratosis / chemically induced. Parakeratosis / pathology

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • MedlinePlus Health Information. consumer health - Vitamin E.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10918562.001).
  • [ISSN] 1354-523X
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antioxidants; 0 / Carcinogens; 0 / Drug Combinations; 1406-18-4 / Vitamin E; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


5. Bhatia N: Imiquimod as a possible treatment for keratoacanthoma. J Drugs Dermatol; 2004 Jan-Feb;3(1):71-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To date, the approved use is for condyloma acuminata; approval for use in treating basal cell carcinoma (BCC) has been filed with the FDA and is expected to be approved in the coming months.
  • In the interim, the expansion of the horizons for this immunomodulator depends on the application of the science and immunology behind the drug to the appropriate disease states.
  • There are studies currently underway as well as anecdotal data published for its possible use in treating squamous cell carcinoma (SCC), although this is not as widely accepted for off-label use as BCC among many dermatologists.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Keratoacanthoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Aged. Cheek. Female. Humans






Advertisement